

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3651251

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	TRIER PHARMA APS	09/25/2015
RECEIVING PARTY DATA		
Name:	ABBA PHARMA LIMITED	
Street Address:	C/O BDO CHARTERED ACCOUNTANTS & ADVISORS, AL FUTTAIM TOWER	
Internal Address:	OFFICE NO. 303-305, 3RD FLOOR, AL MAKTOUM ROAD DEIRA, P.O. BOX 1961	
City:	DUBAI	
State/Country:	UNITED ARAB EMIRATES	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Patent Number:	6710051
CORRESPONDENCE DATA		
Fax Number:	(949)760-9502	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	949-760-0404	
Email:	efiling@knobbe.com	
Correspondent Name:	ERIC S. FURMAN	
Address Line 1:	KNOBBE MARTENS OLSON & BEAR LLP	
Address Line 2:	2040 MAIN STREET, 14TH FLOOR	
Address Line 4:	IRVINE, CALIFORNIA 92614	
ATTORNEY DOCKET NUMBER:	PLOUG224.001GEN	
NAME OF SUBMITTER:	ERIC FURMAN	
SIGNATURE:	/Eric Furman/	
DATE SIGNED:	12/09/2015	
Total Attachments: 5		
source=Patent Assignment - 7MX - From Trier to Abba - Signed#page1.tif		
source=Patent Assignment - 7MX - From Trier to Abba - Signed#page2.tif		
source=Patent Assignment - 7MX - From Trier to Abba - Signed#page3.tif		
source=Patent Assignment - 7MX - From Trier to Abba - Signed#page4.tif		

ASSIGNMENT

This Assignment is made on with effect from 25th day of September 2015 between **TRIER PHARM APS**, a corporation organized and existing under the Laws of Denmark, whose address is Tingskiftevej 6, DK-2900 Hellerup, Denmark, (hereinafter referred to as "the Assignor") through **Mr. Klaus Trier, Managing Director**, of the one part


and

ABBA PHARMA LIMITED, a corporation organized and existing under the Laws of United Arab Emirates, whose address is c/o. BDO Chartered Accountants & Advisors, Al Futtair Tower, Office No. 303-305, 3rd Floor, Al Maktoum Road Deira, P.O. Box 1961, Dubai, UAE, (hereinafter called "the Assignee") through **Mr. Sunjeev Aurora, Director**, of the other part.

Whereas the Assignor is the Applicant and absolute Owner of the Patent Applications and granted patents listed in the **Annexure 'A'** and all related Intellectual Property Rights, if any (hereinafter referred to as "the invention/s") and whereas the Assignor has agreed to assign to the Assignee all their rights, titles & interest in and to the annexed list of Granted Patent and Patent Applications as well as any and all continuation or divisional application, reissues and extensions of such patent, all priority rights (as well as such rights in any continuations in whole or part or substitute applications filed claiming the benefits of the Patent), including the right to apply for Patent or similar protection for it and in any part of the world,

AND whereas, the Assignor is the absolute owner of Intellectual Property Rights in the clinical and preclinical data, commercial information in subject matter directly or indirectly related to developing and validating clinical/medicinal applications of the subject matter in the assigned patent applications and patents of **Annexure A**, including commercial surveys whether developed in collaboration independently or jointly by Dr. Klaus Trier and Trier Pharma APS or by Trier Pharma and any other collaborator, including but not limited to as specified in the **Annexure 'B'** (hereinafter referred to as "The Data and Data Exclusivity Right"), including Data Exclusivity Rights in the clinical and preclinical data and the Assignor has agreed to assign to the Assignee all their rights, titles & interest in "The Data and Data Exclusivity Right", including but not limited to the items expressly mentioned in the **Annexure 'B'** including right to use such data for any purpose including regulatory purpose in any part of the world and know-how for commercialization of the assigned Intellectual Property Rights across the globe;

AND whereas the right, title and interest (including copyrights, concepts and technologies, trade secrets and trademarks and associated goodwill and patent rights in the invention and the right to registrations of the invention) conveyed in this Assignment as specified in **Annexure 'A'** and **Annexure 'B'** is to be held and enjoyed by Assignee and Assignee's affiliates, subsidiaries, successors as fully and exclusively as it would have been held and enjoyed by Assignor had this assignment not been made;



now this deed witnesseth that for a valuable consideration of the sum of Euro 100/- (One Hundred Euro) paid by the Assignee to the Assignor (the receipt whereof the Assignor hereby acknowledge) the Assignor as the beneficial owner hereby assigns unto the Assignee absolutely his entire rights, titles and interests in: (a) the said "Invention/s" as well as any and all continuation or divisional application, reissues and extensions of such patent, all priority rights, including the right to apply and obtain Patent or similar protection for the same in any part of the world; and (b) "The Data and Data Exclusivity Right".


Assignor hereby represents and warrants that

- i. Assignor is the legal owner of all right, title and interest in the Invention and the Data and Data Exclusivity Right and has the legal right and authority to execute this Assignment in favor of Assignee;
- ii. It has not executed any other agreement that would conflict with the terms of this Assignment, nor shall it execute any such agreement in the future;
- iii. this Assignment does not infringe on the rights of any third party / person;
- iv. to the best of Assignor's knowledge, the Patent is valid and enforceable as of the date of this Assignment;
- v. such rights have not been previously licensed, pledged, assigned or encumbered;

In witness whereof the Assignor and Assignee hereto have executed these presents the day and year first hereunto written.


Dated this 25th day of September 2015.


ASSIGNOR : For TRIER PHARM APS


Signature :
Name : **Klaus Trier**
Designation : **Managing Director**

KLAUS TRIER
Øjenlæge
Tingskiftevej 6, 2900 Hellerup
Tlf. 39 62 56 63
Fax 39 62 56 42

ASSIGNEE : For ABBA PHARMA LIMITED,



Signature :
Name : **Sunjeev Aurora**
Designation : **Director**



ANNEXURE 'A'


SR.NO.	COUNTRY / JURISDICTON	PATENT APPLICATION NO. /PATENT NO.	FILING DATE
1	Denmark	DK19970000009 19970106	06.01.1997
2	Denmark	DK19970000823 19970707	07.07.1997
3	Denmark	DK19970001383 19971201	01.12.1997
4	United States of America	US6710051	01.06.1999
5	Canada	CA 2276287	28.06.1999
6	Patent Cooperation Treaty application	PCT/DK/1998/000001	05.01.1998

ASSIGNOR : For TRIER PHARM APS


 Signature :
 Name : **Klaus Trier**
 Designation : **Managing Director**
 KLAUS TRIER
 Øjenlæge
 Tingskiftevej 6, 2900 Hellerup
 Tlf. 39 62 56 63
 Fax 39 62 56 42

ASSIGNEE : For ABBA PHARMA LIMITED


 Signature :
 Name : **Sunjeev Aurora**
 Designation : **Director**




ANNEXURE 'B'


S. No.	Particulars of the Know-how / Data and Data Exclusivity Rights
1	Innovative solutions, developed up-to the date of this agreement, to human vision problems and the elimination of blindness due to refractive error and has formed working relationships with educational, research and commercial participants in the ophthalmic industry around the world
2	Technology and know-how relating to the treatment of myopia owned by the Assignor (Trier Pharm APS) using 7-methylxanthine (7-MX), which has been developed and trialed for the last 20 years in Denmark, based on the work of Dr Klaus Trier, ophthalmologist (Dr Trier)
3	information relating to the dosage, formulation or administration of 7-MX to trial patients, including the form of any drug or medium for administration (for example tablets, eye drops)
4	Know-how and insight developed in product packaging
5	Information on (a) collaborators or researchers in the relevant field, (b) suppliers or sources of 7-MX anywhere in the world, (c) manufacturers of alternatives to 7-MX anywhere in the world, (d) potential markets, sellers or distributors of products using 7-MX as a treatment for myopia
6	Any information available on opportunities in commercialization 7-Methyl Xanthine
7	Any other aspect of know-how that is owned by the Assignor (Trier Pharm APS) useful for commercialization of the subject matter of the patents Assigned in Annexure A, as expressly added here by the Assignor
8	Any other aspect of know-how that is owned by the Assignor (Trier Pharm APS) and is useful for working or commercialization of the technology and subject matter of the patents Assigned in Annexure A, and has not been specifically identified in this table.
9	Invention related know how and data associated with 7-methylxanthine (7-MX).

ASSIGNOR : For TRIER PHARM APS


KLAUS TRIER
 Øjenlæge
 Ningskiltavej 6, 2800 Hellerup
 Tlf. 39 62 56 63
 Fax 39 62 56 42
 Signature :
 Name : **Klaus Trier**
 Designation : **Managing Director**

ASSIGNEE : For ABBA PHARMA LIMITED


Sunjeev Aurora
 Director
 Signature :
 Name :
 Designation :



RECEIPT

We, **TRIER PHARM APS**, a corporation organized and existing under the Laws of Denmark, whose address is Tingskiftevej 6, DK-2900 Hellerup, Denmark, (the '**Assignor**' herein) hereby acknowledges the receipt of a sum of **Euros 100** (One Hundred Euros) from **ABBA PHARMA LIMITED**, c/o. BDO Chartered Accountants & Advisors, Al Futtain Tower, Office No. 303-305, 3rd Floor, Al Maktoum Road Deira, P.O. Box 1961, Dubai, UAE, (the '**Assignee**' herein) in pursuance of the Assignment which has an effect from 25th September 2015.

We say received

For **TRIER PHARM APS**


KLAUS TRIER

Øjenlæge

Tingskiftevej 6, 2900 Hellerup

Tlf. 39 62 56 63

Fax 39 62 56 42

Signature : 

Name **Klaus Trier**

Designation : **Managing Director**